Cohn, David E <br/><br/>
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Apr 2011 
 - 1247-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Webcast 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.32.1075  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Chemotherapy, Adjuvant<br/>Computer Simulation<br/>Cost-Benefit Analysis<br/>Disease-Free Survival<br/>Drug Costs<br/>Female<br/>Humans<br/>Intestinal Perforation--economics<br/>Models, Economic<br/>Neoplasm Staging<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Randomized Controlled Trials as Topic<br/>Survival Analysis<br/>Survival Rate<br/>Time Factors<br/>Treatment Outcome